A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Name: A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
License: Public Domain

Oxford Biodynamics Inc.

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

cancer immunotherapy

cancer, immunotherapy, pd-1, pd-l1, immune checkpoint therapy

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 143556
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.